Sommerfeld
Marc Sommerfeld, Birkweiler DE
Patent application number | Description | Published |
---|---|---|
20110297862 | Valve flap device - A valve flap device for an exhaust system of a motor vehicle, having at least one tubular valve housing with a flow cross section running perpendicular to a central axis and being formed by the inner geometry and a shaft which can turn about a valve axis with a valve flap mounted on the shaft, being mounted in the valve housing to close the flow cross section. The valve flap device can be made with low material input and at the same time with low fabrication expense at low costs. For this, the valve housing is made from a tubular blank of sheet metal with a tube diameter that is calibrated to the flow cross section at least partially by mechanical, plastic forming. | 12-08-2011 |
Marcel Sommerfeld, Walldorf DE
Patent application number | Description | Published |
---|---|---|
20140258838 | EXPENSE INPUT UTILITIES, SYSTEMS, AND METHODS - Systems and methods for expense input utilities include providing an image of an expense-related document for display with an expense form. A selection of a portion of the image and a selection of an input field of the expense form may be received. Optical character recognition may be performed on the selected portion of the image to identify a text string and the selected input field may be populated with the identified text string. Metadata associated with the input field may be associated with the text string and the expense form may be converted into structured data that includes the metadata and the text string. | 09-11-2014 |
Mark Sommerfeld, Bensheim DE
Patent application number | Description | Published |
---|---|---|
20110077197 | NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE - The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4. | 03-31-2011 |
20110173722 | NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE - The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof. | 07-14-2011 |
Mark Sommerfeld, Frankfurt Am Main DE
Patent application number | Description | Published |
---|---|---|
20130203651 | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 08-08-2013 |
20140073563 | FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME - The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas. | 03-13-2014 |
20140142023 | Pharmaceutical Composition for Treating A Metabolic Syndrome - The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 05-22-2014 |
Mark Sommerfeld, Bernsheim DE
Patent application number | Description | Published |
---|---|---|
20150231210 | Pharmaceutical Composition for Treating a Metabolic Syndrome - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 08-20-2015 |
Peter Sommerfeld, Essen DE
Patent application number | Description | Published |
---|---|---|
20160006160 | SEALED CONNECTOR AND METHOD OF SEALING A CONNECTOR - A sealed insert molded connector and method of sealing the same includes one or more inserts molded into a housing so that at least one portion of the insert extends through the housing. A bonding region is formed at the point where the insert extends through the housing. The conformal coating or sealing material is applied to the bonding region where the molded housing forms the insert creating a moisture resistant seal between the housing and the insert. The viscosity of the sealing material is chosen so that the sealing material exhibits minimum travel under the influence of gravity. A collar forming a moat or well around the bonding agent may be formed. | 01-07-2016 |
Sven Sommerfeld, Schwelm DE
Patent application number | Description | Published |
---|---|---|
20100331530 | METHOD FOR PURIFYING THERAPEUTIC PROTEINS BY MEANS OF MULTI-STAGE EXTRACTION - Method for purifying therapeutic proteins by multi-stage extractive distillation. | 12-30-2010 |
20110223322 | PRODUCTION OF CONDUCTIVE SURFACE COATINGS USING A DISPERSION CONTAINING ELECTROSTATICALLY STABILISED SILVER NANOPARTICLES - The present invention relates to a process which comprises: providing a substrate having a surface; applying a dispersion to the surface, wherein the dispersion comprises at least one liquid dispersant, and electrostatically stabilised silver nanoparticles having a zeta potential of from −20 to −55 mV in the dispersant at a pH value of from 2 to 10; and heating one or both of the surface and the dispersion applied thereon to a temperature of from 50° C. below the boiling point of the dispersant to 150° C. above the boiling point of the dispersant, to form a conductive coating on the surface. | 09-15-2011 |
Timothy James Sommerfeld, Ariss CA
Patent application number | Description | Published |
---|---|---|
20110293887 | METHOD AND APPARATUS FOR IMPRINTING A THREE-DIMENSIONAL DESIGN INTO A SYNTHETIC MATERIAL - A method, product, and apparatus for imprinting a three-dimensional design into a textured surface of a synthetic material includes laser-ablating the design into the synthetic material and then imprinting the design. The design is laser-ablated into the textured surface of the synthetic material by vaporizing a portion of the material in an x-y shape of the design to a predetermined z-depth. The vaporized portions of the material form a design-shaped void that extends a prescribed distance into the textured surface of the synthetic material. In one implementation, the design is imprinted by inserting a tool in the design-shaped void of the laser-ablated design. The tool has a substantial conformance fit with the void, thereby forming a substantially distortion-free imprint of the design on the synthetic material. | 12-01-2011 |
Tobias Sommerfeld, Buchholz DE
Patent application number | Description | Published |
---|---|---|
20140252851 | Method and Device for Generating Electrical Energy in a Motor Vehicle - A method and device for generating electrical energy in a motor vehicle involves thermoelectric generator having a plurality of thermoelectric modules and coupled to at least one electrical consumer. Module open-circuit voltages of the modules are determined and those modules for which a sum of their module open-circuit voltages attains twice a predefined generator output voltage with the smallest possible deviation are determined and electrically connected to one another in series. | 09-11-2014 |